Screener
GeneDx Holdings WGS Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $114.44M+11.4% | $102.25M+17.4% | $120.99M+26.5% | $116.74M+51.9% | $102.69M+45.6% | ||
| $36.2M+13.9% | $34.04M+18.9% | $36.72M+24.8% | $32.22M+10.9% | $31.79M+15.3% | ||
| $78.24M+10.3% | $68.21M+16.6% | $84.27M+27.3% | $84.53M+76.7% | $70.9M+65.1% | ||
| 68.4%-0.7pp | 66.7%-0.4pp | 69.6%+0.4pp | 72.4%+10.2pp | 69%+8.1pp | ||
| $19.66M+30.4% | $19.8M+57.5% | $24.54M+112% | $19.83M+70.0% | $15.08M+38.3% | ||
| $76.04M— | $74.59M+47.9% | —— | —— | —— | ||
| -$1.19M-45.0% | -$717K-12.0% | -$520K+25.5% | -$562K+33.3% | -$817K+8.6% | ||
| -$803K-150% | -$4.95M-223% | -$4M-17.8% | -$4.14M-615% | $1.6M+109% | ||
| -$17.74M-264% | -$63.32M-870% | -$17.67M— | -$7.64M+8.1% | $10.81M+137% | ||
| -15.5%-26.0pp | -61.9%-54.4pp | -14.6%— | -6.5%+4.3pp | 10.5%+51.9pp | ||
| -$10.74M-171% | -$50.66M-4,595% | -$7.35M— | $3.22M+274% | $15.15M+383% | ||
| -9.4%-24.1pp | -49.5%-50.8pp | -6.1%— | 2.8%+5.2pp | 14.8%+22.4pp | ||
| -$17.46M-295% | -$57.47M-1,163% | -$14.24M— | -$3.25M+58.2% | $8.96M+185% |
FAQ
- What is GeneDx Holdings's revenue?
- GeneDx Holdings (WGS) generated $454.4M in revenue over the trailing twelve months, up 25.4% year over year.
- Is GeneDx Holdings profitable?
- GeneDx Holdings is not currently profitable: it reported a net loss of $106.4M over the trailing twelve months, a -23.4% net margin.
- What are GeneDx Holdings's profit margins?
- Gross margin is 69.4% and operating margin is -20.3%, with a -23.4% net margin.
- What is GeneDx Holdings's earnings per share?
- GeneDx Holdings's diluted EPS over the trailing twelve months is $-3.64.
- Where does GeneDx Holdings's income statement data come from?
- Every line is extracted from GeneDx Holdings's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
